SCHEMBL4186840

SCHEMBL4186840

COc1ccc(S(=O)(=O)N2CCN(S(=O)(=O)c3ccc(OC)c(OC)c3)C2=O)cc1OC

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPBAR1 Q8TDU6 1/20 0.63
TSHR P16473 3/20 0.61
MAPK1 P28482 2/20 0.61
POLB P06746 2/20 0.61
PDE4A P27815 2/20 0.60
PDE4B Q07343 2/20 0.60
PDE4C Q08493 2/20 0.60
PDE4D Q08499 2/20 0.60
SMN1; SMN2 Q16637 2/20 0.57
CYP3A4 P08684 1/20 0.57
CYP2C19 P33261 1/20 0.57
NPSR1 Q6W5P4 1/20 0.57
CMA1 P23946 2/20 0.54
CTSG P08311 1/20 0.54
LMNA P02545 2/20 0.53
HSD17B10 Q99714 2/20 0.53
USP2 O75604 1/20 0.53
GLA P06280 1/20 0.53
HTT P42858 2/20 0.52
PKM P14618 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4180134 0.90 GPBAR1 (0.63) GPBAR1TSHRMAPK1POLBPDE4A
SCHEMBL4180004 0.84 PDE4A (0.78) GPBAR1TSHRMAPK1POLBPDE4A
SCHEMBL4186821 0.84 GPBAR1 (0.68) GPBAR1TSHRMAPK1POLBPDE4A
SCHEMBL4186363 0.82 GPBAR1 (0.68) GPBAR1TSHRMAPK1POLBPDE4A
SCHEMBL3830421 0.81 GPBAR1 (0.90) GPBAR1TSHRMAPK1POLBSMN1; SMN2
SCHEMBL4184681 0.81 GPBAR1 (0.90) GPBAR1TSHRMAPK1POLBSMN1; SMN2
SCHEMBL4187995 0.81 GPBAR1 (0.73) GPBAR1TSHRMAPK1POLBSMN1; SMN2
SCHEMBL7209087 0.79 GPBAR1 (0.91) GPBAR1TSHRMAPK1POLBSMN1; SMN2
SCHEMBL6367892 0.79 GPBAR1 (0.97) GPBAR1TSHRMAPK1POLBSMN1; SMN2
SCHEMBL6977881 0.78 GPBAR1 (0.73) GPBAR1TSHRMAPK1POLBSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090069302-A1 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2009-03-12 US claimed
US-20090069302-A1 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2009-03-12 US disclosed
US-20090069302-A1 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2009-03-12 US disclosed
US-20090069302-A1 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2009-03-12 US disclosed
WO-2007127505-A2 USE OF SULFONAMIDE DERIVATIVES IN THE TREATMENT OF DISORDERS OF THE METABOLISM AND THE NERVOUS SYSTEM SMITHKLINE BEECHAM CORPORATION (US) 2007-11-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069302-A1 CHEMICAL COMPOUNDS TBXA2R, PDE4D, PDE4A GPBAR1 81/4885TSHR 576/4885MAPK1 1720/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.